Various immune checkpoints have been identified, with the PD-1/PD-L1 pathway being a prominent target for cancer immunotherapy and several approved monoclonal antibody therapies, such as Nivolumab by Bristol-Myers Squibb and Pembrolizumab by Merck. Here, CD274 is linked to cancer.